<DOC>
	<DOCNO>NCT00842998</DOCNO>
	<brief_summary>This study evaluate activity single agent trastuzumab lapatinib patient previously treat HER-2 positive ( FISH positive ) metastatic breast cancer . A companion biological study assess factor correlate sensitivity resistance either one compound</brief_summary>
	<brief_title>Efficacy Study Single Agent Trastuzumab Lapatinib Treat HER2-Overexpressing Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women age 1875 year Histologically cytologically confirm metastatic disease . HER2Overexpression proven Fluorescence Situ Hybridization ( FISH ) . Availability paraffinembedded block either primitive tumor and/or biopsy metastasis . No prior chemotherapy metastatic locally advanced disease . Patients hormone receptor ( oestrogen and/or progesterone ) positive breast cancer eligible provide receive ONE line hormonal therapy metastatic disease . For patient undergoing hormonal therapy metastatic disease , disease progression must confirm accord RECIST criterion . At least 20 % increase sum long diameter , OR Evidence new metastatic lesion progression preexist nontarget lesion . Presence least one monodimensionally measurable lesion . Patients without clinically radiologically proven evidence disease eligible . Patients exclusively skin disease eligible , provided disease evolution treatment photographically document . Patients involvement NCS , besides presence measurable lesion , eligible provide : Brain lesion/s has/have radically resect ; Brain lesion/s has/have obtain complete remission follow radiation therapy . Complete remission must document TC RMN . At least 4week interval end radiotherapy , hormono immunotherapy enrollment study . ECOG PS &lt; /= 2 life expectancy least 6 month . Liver metastases involve &lt; 30 % liver volume . Adequate hematopoietic , liver renal function Written inform consent . Patients childbearing potential must negative pregnancy test must use adequate contraceptive measure treatment . Prior treatment Trastuzumab adjuvant therapy permit provide complete least 12 month prior enrollment study . Prior chemotherapy metastatic disease . Active pregnancy breastfeeding . Previous treatment Lapatinib . Previous therapy mono policlonal antibody metastatic disease . Patients bone involvement pleural effusion/ascites unique localization disease . Patients dyspnea due presence disease ( lymphangitis ) require oxygen therapy . Patients clinically evident hearth disease and/or active infectious disease . Patients resect irradiated brain and/or leptomeningeal metastasis . Prior actual concurrent neoplasm , exception adequately treat carcinoma della cervice uterina basal cell squamocellular carcinoma skin . Patients uncontrolled serious illness may compromise compliance patient treatment . Previous allergic reaction towards excipient composition Trastuzumab Lapatinib . Use experimental drug within 4 week prior initiation study treatment . Women childbearing potential refuse use adequate contraceptive measure . Patients unable give write informed consent compliant treatment . Patients great tumor involvement ( &gt; 30 % dof hepatic volume , etc ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>HER2 gene-amplification</keyword>
</DOC>